• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Neutralizing Antibodies to SARS-CoV-2 Persist for at Least 5 Months

November 3, 2020

Since December 2019, SARS-CoV-2 has infected over 46 million individuals worldwide leading to over 1 million deaths.  While the majority of cases of COVID-19 have mild-to-moderate symptoms, the antibody responses in less severe infections are not well characterized.  In order to gain a better understanding of the longevity and robustness of antibody responses in less severe cases of COVID-19, researchers in New York City screened 72,401 individuals with confirmed or suspected COVID-19 for SARS-CoV-2 antibodies.  Over 30,030 individuals tested positive for SARS-CoV-2 antibodies with over 90% of individuals having moderate to high levels of anti-spike antibodies (>1:320 detected by ELISA).  In 121 patients with COVID-19 followed over 5 months, the geometric mean titer of anti-spike antibodies declined from 764 to 404.  Furthermore, levels of anti-spike antibodies correlated with neutralization antibodies (Spearman’s r=0.87, p<0.0001).  Researchers plan to follow these individuals over a longer period of time to determine how stable SARS-CoV-2 antibodies are over time and whether they provide protection from re-infection.  A better understanding of the longevity and kinetics of SARS-CoV-2 antibodies will also provide valuable information for understanding ideal donors of convalescent plasma and hyperimmune globulin.

Reference:

Wajnberg A, Amanat F, Firpo A, Altman DR, et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.  Science Magazine 2020

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • Chagas Disease Screening for Family Members of Positive Blood Donors

  • Multicenter Study Finds No Correlation between Chronic Fatigue Syndrome and XMRV

  • Female Blood Donors at Risk for Iron Deficiency

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley